Jeremie Tordo

Jeremie Tordo

Auto-generated profile, based on publicly available information

Jeremie Tordo

Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
EBEstelle Bourbon
Estelle Bourbon
PSPIERRE SESQUES
PIERRE SESQUES
MGMorgane Gossez
Morgane Gossez
JTJérémie Tordo
Jérémie Tordo
EFEmmanuelle Ferrant
Emmanuelle Ferrant
FVFabienne Venet
Fabienne Venet
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR expression on monocytes (mHLA-DR) before and after commercial anti-CD19 CAR T-cell infusion in a large cohort (n = 103) of patients with R/R LBCL and its association with adverse events and treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR in 79% of the cases, whereas in 2l% of cases (15 patients), the mHLA-DR level decreased after LD, and this decrease was associated with poorer outcome. Low mHLA-DR at day minus 7 (D−7) (<13 500 antibodies per cell) before CAR T-cell infusion correlated with older age, poorer performance status, higher tumor burden, and elevated inflammatory markers. With a median follow-up of 7.4 months, patients with low mHLA-DR D−7 exhibited a poorer duration of response and survival than the higher mHLA-DR D−7 group. For toxicity management, tocilizumab was more frequently used in the low–mHLA-DR D−7 group. These data suggest that monocyte dysregulation before LD, characterized by the downregulation of mHLA-DR, correlates with an inflammatory and immunosuppressive tumor environment and is associated with failure of anti-CD19 CAR T cells in patients with R/R LBCL. Modulation of these myeloid cells represents a promising field for improving CAR therapy.

3 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ASAndrea Skanjeti
Andrea Skanjeti
NMNicolas Magand
Nicolas Magand
DDDidier Defez
Didier Defez
JTJeremie Tordo
Jeremie Tordo
ARAgnes Rode
Agnes Rode
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
Selective Internal Radiation Therapy (SIRT) is used for the treatment of hepatic tumors. The aim of this retrospective study was to compare two dosimetric approaches based on 99mTc-MAA SPECT/CT and 90Y PET/CT, using Simplicit90Y™ versus the supplier suggested method of activity calculation. A total of 19 patients underwent 21 SIRT after baseline angiography and 99mTc-MAA SPECT/CT, followed by 90Y PET/CT. Overlap between 99mTc-MAA and 90Y-microspheres was quantified with different thresholds isocontours. The perfused volume and tumor absorbed dose were estimated using Simplicit90Y™ based on SPECT/CT and PET/CT, then compared with the supplier suggested method. These data were related to overall survival to evaluate their prognostic impact. The overlap between PET/CT and SPECT/CT was dependent on thresholds, decreasing with an increasing threshold. The overlap between the 99mTc-MAA and 90Y-microspheres biodistributions versus the tumor distribution on morphological imaging was suboptimal, in particular for small tumor volume. The tumor absorbed dose estimated after 90Y PET/CT was not different from tumor absorbed dose estimated after SPECT/CT. The Perfused lobe absorbed dose was significantly lower while the volume of the perfused lobe was significantly higher when estimated by Simplicit90Y™ compared to the supplier suggested conventional approach. A statistical parameter based on overlap between tumor and 90Y-microspheres distribution as well as tumoral dosimetry was significantly related to the overall survival. Post-treatment imaging remains paramount to estimate the irradiation dosimetry, due to an imperfect overlap. The perfused volume could be estimated from functional imaging, given its impact on dosimetry. Finally, survival seems related to tumoral overlap and dosimetry.

1 June 2022 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
MDMatthieu Dietz
Matthieu Dietz
JTJeremie Tordo
Jeremie Tordo
A 54-year-old man, with previous history of neurogenic heterotopic ossification (HO) in muscles around the left hip following a spinal cord injury ten months earlier, was referred to our nuclear medicine center for an isfluorine-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) to rule out a spondylodiscitis. No sign of spondylodiscitis was found on F-18-FDG PET/CT, but images revealed an increased F-18-FDG uptake in HO areas, matching with ongoing osteoblastic activity on a following bone scan.

1 July 2021 in Annales de Pathologie
Verified
Journal Article
Closed access
SNSophie Neyrand
Sophie Neyrand
JFJuliette Fontaine
Juliette Fontaine
JTJeremie Tordo
Jeremie Tordo
JLJean-Christophe Lifante
Jean-Christophe Lifante
MDMyriam Decaussin-Petrucci
Myriam Decaussin-Petrucci